Skip to content
  • Clinical Evidence
  • PAD
    • PAD
    • DETOUR System
    • DETOUR System Evidence
    • DETOUR System Resources
    • DETOUR System Reimbursement
  • AAA
    • AAA
    • ALTO
    • AFX2
    • EVAR for Women
    • EVAR Portfolio Resources
  • Procedural Training
  • For Patients
  • About Us
    • About Us
    • News
    • The Team
    • Careers
    • Contact Us
  • Clinical Evidence
  • PAD
    • PAD
    • DETOUR System
    • DETOUR System Evidence
    • DETOUR System Resources
    • DETOUR System Reimbursement
  • AAA
    • AAA
    • ALTO
    • AFX2
    • EVAR for Women
    • EVAR Portfolio Resources
  • Procedural Training
  • For Patients
  • About Us
    • About Us
    • News
    • The Team
    • Careers
    • Contact Us
Back to News
  • November 15, 2017

VEITH 2017 Presentation: Status of the LEOPARD Trial: Comparing the AFX Endologix Graft to other Standard EVAR Endografts

PrevPreviousEndologix Appoints John Onopchenko as Chief Operating Officer
NextEndologix Appoints Greg Morrow as Chief Marketing Officer and Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Next
FIND IFU HERE
Youtube Linkedin Twitter

Compliance

Privacy Policy

Safety Information

Anti-Trafficking/Modern Slavery

Cookie Policy

Terms & Conditions

Patents

© 2025 Endologix LLC. All rights reserved.

Endologix® products and associated components are not available in all countries or regions. Please contact your Endologix representative for details regarding product availability. Prior to use, refer to the “Instructions for Use” for complete and specificindications, contraindications, all warnings and precautions. Rx only.